Frequency of First Generic Drug Approvals With “Skinny Labels” in the United States-Reference-Cited by-同舟云学术

Frequency of First Generic Drug Approvals With “Skinny Labels” in the United States

Published:2021-03-29 Issue: Volume: Page:
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Walsh Bryan S.¹,Sarpatwari Ameet¹,Rome Benjamin N.¹,Kesselheim Aaron S.¹

Affiliation:

1. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2777965/jamainternal_walsh_2021_ld_210007_1616514951.51976.pdf

Reference5 articles.

1. Strategies that delay market entry of generic drugs.;Vokinger;JAMA Intern Med,2017

2. Market exclusivity length for drugs with new generic or biosimilar competition, 2012-2018.;Rome;Clin Pharmacol Ther,2021

3. Richards? KT, Ward? EH, Hickey? KJ. Drug pricing and pharmaceutical patenting practices. Congressional Research Service. February 11, 2020. Accessed February 8, 2021. https://www.everycrsreport.com/files/20200211_R46221_145095cd7a7d37a957722140d6e708a1d52de5a1.pdf

4. US Federal Food, Drug, and Cosmetic Act, 21 USC §355 (2018). Accessed February 8, 2021. https://www.govinfo.gov/content/pkg/USCODE-2010-title21/pdf/USCODE-2010-title21-chap9-subchapV-partA-sec355.pdf

5. Bloomfield? D. Speech, drugs, and patent inducement. February 4, 2021. Accessed February 15, 2021. https://ssrn.com/abstract=3744403

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing supplemental indications for cancer drugs approved in the US and EU;European Journal of Cancer;2024-09

2. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label;Annals of Internal Medicine;2024-06

3. Generic Drugs and the Struggle to Compete: The Role of Skinny Labels;Clinical Therapeutics;2024-05

4. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending;Value in Health;2024-04

5. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals;Health Affairs;2024-01-01